

GENE Life to leverage anti-pandemic supplies and COVID-19 kits in China

07 October 2020 | News

Amuse Group, Grand view Bio-Tech and Mason Supreme Healthcare to leverage industry network and expertise in Hong Kong and the Greater Bay area



Amuse Group Holding Limited and Grand View Bio Tech announced the establishment of their joint venture GENE Life Company Limited. Leveraging both companies' expertise and market edges, GENE Life is dedicated to engaging in assembling and the sale of anti-pandemic products, which include COVID-19 test kits, in Hong Kong and the Greater Bay Area.

While the materials of COVID-19 test kits serve as the primary product of GENE Life, the Company offers other products including face masks and immunity-boosting nutritional supplements.

With an aim to enhancing its product diversity and sales channels, Grand View, the shareholder of GENE Life, had previously signed the Memorandum of Understanding (MOU) with Mason Supreme Healthcare ("MSH"), a subsidiary company of Mason Group Holdings Limited which core business is to provide medical consultancy and health management services in the Greater Bay Area.

"GENE Life is here to meet rising demand of the anti-pandemic products. We will leverage the expertise and market edges of our shareholders and other business partners, which include Grand View's rich experience in trading business of face masks and COVID-19 test kits, and MSH's healthcare expertise and resources. Together with the investment of Amuse Group, we will promote our quality anti-pandemic products to the citizens in Hong Kong and the Greater Bay Area", said Ms. Kammy Cheung, the CEO of GENE Life.

Image Caption: (From second left to right) GENE Life Image Ambassador: Miss Kiko Leung, Mason Supreme Healthcare Group: Dr. Keith Wong, GENE Life Chief Executive Officer: Miss Kammy Cheung, Representative of Grand View Bio Tech: Mr Raymond Leung, GENE Life General Manager: Miss Candy Leung